A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
Latest Information Update: 21 Apr 2020
At a glance
- Drugs Enzalutamide (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 16 Jan 2018 Status changed from not yet recruiting to completed.
- 04 Nov 2017 New trial record